GPO Of Thailand To Quadruple Production Of Tamiflu Generic
This article was originally published in PharmAsia News
Executive SummaryThailand's Government Pharmaceutical Organization has decided to increase production of its generic of Roche's Tamiflu (oseltamivir) antiviral to deal with a sharp increase in cases of H1N1 flu virus. GPO's director general said the firm expects to receive the API from India next week and begin production immediately. GPO, which also is working on an H1N1 vaccine, produces its Tamiflu generic under a controversial law that allows the government to circumvent patent protection on certain vital drugs when it deems such action necessary. The current 10 million-dose production level is to be increased to 40 million, GPO said. (Click here for more
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.